县医院医生作为共同第一作者发表《新英格兰医学杂志》论文，为脑中风治疗带来新策略

Core Viewpoint - The article discusses the efficacy of Tirofiban, a platelet glycoprotein IIb-IIIa receptor antagonist, in improving functional outcomes for patients with acute ischemic stroke who receive intravenous thrombolysis within 4.5 hours of symptom onset [3][11]. Group 1 - Intravenous thrombolysis remains the standard treatment for acute ischemic stroke within 4.5 hours, and the use of antiplatelet drugs may prevent reocclusion in the first 24 hours post-thrombolysis [2]. - The ASSET-IT trial, published in NEJM, involved 832 patients with non-cardiogenic stroke who received thrombolysis and assessed the impact of early Tirofiban infusion on functional outcomes [3][10]. - The study was led by Professor Wei Hu from the First Affiliated Hospital of the University of Science and Technology of China, with contributions from multiple co-authors [6]. Group 2 - The trial was a multicenter, double-blind, randomized controlled study conducted across 38 medical centers in China, focusing on patients who were not candidates for thrombectomy [9]. - Patients were randomly assigned to receive either Tirofiban or a placebo within 60 minutes after thrombolysis, with the primary outcome being the proportion of patients achieving a good functional outcome at 90 days [10]. - Results indicated that 65.9% of the Tirofiban group achieved a good functional outcome compared to 54.9% in the placebo group, with a hazard ratio of 1.20 [11]. Group 3 - The incidence of symptomatic intracranial hemorrhage was 1.7% in the Tirofiban group versus 0% in the placebo group, while the mortality rate at 90 days was 4.1% for Tirofiban and 3.8% for placebo [11]. - The study fills an evidence gap regarding the use of antiplatelet drugs in the post-thrombolysis window for stroke patients, providing high-quality evidence to optimize treatment strategies in China [12].